The aMAP (Age, Male, Albumin–Bilirubin, Platelets) score, first developed by Fan et al. in 2020, is a validated HCC risk model that incorporates age, sex, albumin–bilirubin (ALBI) score, and platelet count [97]. Here, ALB is linked to hepatocellular carcinoma.